Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25573773
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25573773
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Cold+Spring+Harb+Perspect+Med
2015 ; 5
(5
): a017822
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Tuberculosis treatment and drug regimens
#MMPMID25573773
Sotgiu G
; Centis R
; D'ambrosio L
; Migliori GB
Cold Spring Harb Perspect Med
2015[Jan]; 5
(5
): a017822
PMID25573773
show ga
Tuberculosis is an airborne infectious disease treated with combination
therapeutic regimens. Adherence to long-term antituberculosis therapy is crucial
for maintaining adequate blood drug level. The emergence and spread of
drug-resistant Mycobacterium tuberculosis strains are mainly favored by the
inadequate medical management of the patients. The therapeutic approach for
drug-resistant tuberculosis is cumbersome, because of the poor, expensive,
less-effective, and toxic alternatives to the first-line drugs. New
antituberculosis drugs (bedaquiline and delamanid) have been recently approved by
the health authorities, but they cannot represent the definitive solution to the
clinical management of drug-resistant tuberculosis forms, particularly in
intermediate economy settings where the prevalence of drug resistance is high
(China, India, and former Soviet Union countries). New research and development
activities are urgently needed. Public health policies are required to preserve
the new and old therapeutic options.
free
free
free
